Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Mar 15, 2026
Reporting period
Not applicable
Filed with the SEC
Mar 17, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001061983-26-000023
Filed / recorded
Mar 17, 2026, 8:08 PM UTC
Added to OQRO
Oct 6, 2026, 7:14 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
CYTOKINETICS INC
Issuer CIK
1061983
Ticker
CYTK
Reporting person
Andrew Callos
Relationship
Officer
Officer title
EVP, Chief Commercial Officer
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Mar 15, 2026
Transaction code
A
Shares / units
20,646
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
68,504
Ownership form
Direct
Amendment
No
Footnotes from the filing
Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan.